Revvity (RVTY) Stock Price

Revvity Price

NYSE·CLOSED
124.75USD+0.62 (+0.50 %)
Market closed

Over the last 19 years Revvity grew revenue by 3.3% annually, reaching 2.86 B USD. Earnings per share have grown at 4.5% per year over the last 19 years. For Revvity, the net margin of 8.5% is down versus 24.6% a few years ago. At today's price the dividend yield works out to roughly 0.22%. The payout ratio is around 13% of earnings. The consensus 12-month price target for Revvity is 118.83 USD, about 4.7% below where the stock trades today. Of 26 analysts, 15 rate the stock a buy — an overall Buy consensus. The stock trades about 52% above its 52-week low.

Revvity stock price

Volume
Ex-Dividend
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Revvity over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Revvity stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Revvity's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Revvity Stock Price History
DateRevvity Price
8/21/2026124.75 USD
8/20/2026124.13 USD
8/19/2026120.33 USD
8/18/2026115.15 USD
8/14/2026116.84 USD
8/13/2026117.50 USD
8/12/2026117.88 USD
8/11/2026115.73 USD
8/10/2026115.60 USD
8/7/2026114.66 USD
8/6/2026114.24 USD
8/5/2026114.58 USD
8/4/2026111.67 USD
8/3/2026115.22 USD
7/31/2026112.52 USD
7/30/2026113.54 USD
7/29/2026110.97 USD
7/27/2026109.54 USD
7/23/2026113.17 USD
7/22/2026110.54 USD
7/21/2026110.52 USD
7/20/2026106.44 USD
7/17/2026110.15 USD
7/16/2026111.70 USD
7/15/2026111.35 USD
7/14/2026111.21 USD
7/13/2026112.03 USD
7/10/2026112.29 USD
7/9/2026112.95 USD
7/8/2026110.65 USD
7/7/2026112.05 USD
7/6/2026112.00 USD
7/2/2026113.76 USD
7/1/2026112.84 USD
6/30/2026111.26 USD
6/29/2026111.39 USD
6/26/2026113.02 USD
6/25/2026113.53 USD
6/24/2026105.63 USD
6/23/202699.90 USD
6/22/202699.24 USD
6/18/202698.48 USD
6/17/202699.37 USD
6/16/2026100.65 USD
6/15/2026100.69 USD
6/12/2026100.70 USD
6/11/202699.78 USD
6/10/2026104.01 USD
6/9/2026104.13 USD
6/8/2026100.30 USD
6/5/202698.89 USD
6/4/2026103.52 USD
6/3/2026101.47 USD
6/2/202699.55 USD
6/1/2026103.56 USD
5/29/2026101.95 USD
5/28/2026101.18 USD
5/27/202696.72 USD
5/26/202695.86 USD
5/22/202694.95 USD
5/21/202694.80 USD
5/20/202694.97 USD
5/19/202695.87 USD
5/18/202695.48 USD
5/15/202693.97 USD
5/14/202696.38 USD
5/13/202695.01 USD
5/12/202699.30 USD
5/11/202698.95 USD
5/8/2026101.00 USD
5/7/202698.85 USD
5/6/202699.09 USD
5/5/202692.30 USD
5/4/202686.51 USD
5/1/202686.68 USD
4/30/202686.62 USD
4/29/202682.26 USD
4/28/202685.18 USD
4/27/202686.80 USD
4/24/202686.77 USD
4/23/202687.15 USD
4/22/202694.28 USD
4/21/202694.27 USD
4/20/202693.03 USD
4/17/202693.96 USD
4/16/202689.53 USD
4/15/202692.90 USD
4/14/202693.51 USD
4/13/202692.64 USD
4/10/202689.79 USD
4/9/202690.46 USD
4/8/202690.40 USD
4/7/202687.79 USD
4/6/202688.32 USD
4/2/202688.94 USD
4/1/202687.92 USD
3/31/202687.61 USD
3/30/202684.78 USD
3/27/202683.90 USD
3/26/202687.12 USD
3/25/202687.84 USD
3/24/202687.46 USD
3/23/202687.16 USD
3/20/202685.94 USD
3/19/202685.76 USD
3/18/202685.76 USD
3/17/202687.37 USD
3/16/202686.48 USD
3/13/202685.57 USD
3/12/202684.76 USD
3/11/202689.63 USD
3/10/202690.30 USD
3/9/202692.11 USD
3/6/202691.34 USD
3/5/202696.57 USD
3/4/202698.49 USD
3/3/202695.95 USD
3/2/202695.59 USD
2/27/202698.31 USD
2/26/202699.01 USD
2/25/202697.57 USD
2/24/202697.62 USD
2/23/202697.12 USD
2/20/2026100.33 USD
2/19/202699.91 USD
2/18/202697.74 USD
2/17/202695.01 USD
2/13/202696.03 USD
2/12/202695.57 USD
2/11/2026101.10 USD
2/10/2026104.75 USD
2/9/2026102.82 USD
2/6/2026101.59 USD
2/5/202699.52 USD
2/4/2026103.83 USD
2/3/2026101.13 USD
2/2/2026107.09 USD
1/30/2026108.80 USD
1/29/2026108.49 USD
1/28/2026108.86 USD
1/27/2026114.61 USD
1/26/2026114.70 USD
1/23/2026116.73 USD
1/22/2026117.75 USD
1/21/2026116.53 USD
1/20/2026111.90 USD
1/16/2026112.50 USD
1/15/2026115.33 USD
1/14/2026111.52 USD
1/13/2026110.14 USD
1/12/2026109.01 USD
1/9/2026104.43 USD
1/8/2026101.71 USD
1/7/2026102.99 USD
1/6/2026105.05 USD
1/5/2026102.06 USD
1/2/202698.15 USD
12/31/202596.75 USD
12/30/202597.43 USD
12/29/202597.11 USD
12/26/202596.75 USD
12/24/202596.78 USD
12/23/202597.58 USD
12/22/202597.77 USD
12/19/202596.24 USD
12/18/202596.26 USD
12/17/202596.77 USD
12/16/202596.27 USD
12/15/202599.08 USD
12/12/2025100.49 USD
12/11/2025103.92 USD
12/10/2025103.51 USD
12/9/202598.78 USD
12/8/202599.79 USD
12/5/2025100.79 USD
12/4/2025102.55 USD
12/3/2025103.26 USD
12/2/2025102.73 USD
12/1/2025102.43 USD
11/28/2025104.41 USD
11/26/2025104.66 USD
11/25/2025105.57 USD
11/24/2025100.58 USD
11/21/202598.27 USD
11/20/202594.02 USD
11/19/202592.25 USD
11/18/202593.06 USD
11/17/202591.06 USD
11/14/202592.73 USD
11/13/202593.40 USD
11/12/202594.13 USD
11/11/202594.31 USD
11/10/202592.28 USD
11/7/202590.78 USD
11/6/202589.52 USD
11/5/202592.57 USD
11/4/202591.69 USD
11/3/202592.97 USD
10/31/202593.59 USD
10/30/202591.02 USD
10/29/202595.30 USD
10/28/202596.45 USD
10/27/202597.16 USD
10/24/202599.51 USD
10/23/202597.57 USD
10/22/202595.68 USD
10/21/202596.89 USD
10/20/202595.31 USD
10/17/202593.72 USD
10/16/202594.00 USD
10/15/202592.12 USD
10/14/202591.14 USD
10/13/202590.98 USD
10/10/202588.24 USD
10/9/202591.66 USD
10/8/202591.77 USD
10/7/202591.19 USD
10/6/202593.38 USD
10/3/202594.01 USD
10/2/202591.46 USD
10/1/202591.52 USD
9/30/202587.65 USD
9/29/202584.20 USD
9/28/202584.20 USD
9/25/202584.06 USD
9/24/202583.04 USD
9/23/202585.71 USD
9/22/202586.27 USD
9/19/202586.73 USD
9/18/202587.76 USD
9/17/202585.39 USD
9/16/202585.28 USD
9/15/202584.00 USD
9/12/202583.50 USD
9/11/202585.68 USD
9/10/202582.50 USD
9/9/202585.04 USD
9/8/202586.28 USD
9/5/202586.63 USD
9/4/202585.70 USD
9/3/202583.36 USD
9/2/202587.87 USD
8/29/202590.11 USD
8/28/202589.23 USD
8/27/202588.59 USD
8/26/202591.23 USD
8/25/202591.94 USD
8/22/202594.36 USD
Access this data via the Eulerpool API

Revvity Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
2.75 B USD
399.49 M USD
-118.38 M USD
Jan 1, 2024
2.76 B USD
410.52 M USD
295.83 M USD
Jan 1, 2025
2.86 B USD
356.64 M USD
241.68 M USD
Jan 1, 2026 (e)
2.85 B USD
540.32 M USD
607.21 M USD
Jan 1, 2027 (e)
3.00 B USD
569.27 M USD
667.13 M USD
Jan 1, 2028 (e)
3.19 B USD
603.92 M USD
734.17 M USD
Jan 1, 2029 (e)
3.37 B USD
639.05 M USD
797.53 M USD
Jan 1, 2030 (e)
3.52 B USD
667.08 M USD
857.61 M USD

Revvity Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 22, 2026, 2:30 PM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
DIV.USD
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
2.102.122.262.782.883.783.833.312.752.762.862.853.003.193.373.52
-5.950.526.6723.143.7831.181.19-13.48-16.940.183.67-0.215.376.095.814.39
44.2045.9645.6145.0344.8552.6259.6053.1648.0747.9953.0853.0853.0853.0853.0853.08
0.930.971.031.251.291.992.281.761.321.321.521.511.591.691.791.87
0.270.310.300.370.410.961.340.780.400.410.360.540.570.600.640.67
12.6414.4213.4813.3214.0525.2835.0123.5914.5114.8812.4618.9518.9518.9318.9618.95
212.00233.00113.00238.00227.00728.00943.00569.00-118.00295.00241.00607.00667.00734.00797.00857.00
34.189.91-51.50110.62-4.62220.7029.53-39.66-120.74-350.00-18.31151.879.8810.048.587.53
0.280.280.280.280.280.280.280.280.280.280.280.280.280.28
112.56110.14110.36111.61111.63112.54126.72126.48123.43121.58113.21113.21113.21113.21113.21113.21
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Revvity generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Revvity retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Revvity's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Revvity has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Revvity's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Revvity stock margins

The Revvity margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Revvity. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Revvity.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
59.62 %
35.01 %
24.64 %
Jan 1, 2022
53.16 %
23.59 %
17.19 %
Jan 1, 2023
48.07 %
14.52 %
-4.30 %
Jan 1, 2024
48.01 %
14.90 %
10.74 %
Jan 1, 2025
53.08 %
12.49 %
8.46 %
Jan 1, 2026 (e)
53.08 %
18.95 %
21.30 %
Jan 1, 2027 (e)
53.08 %
18.95 %
22.21 %
Jan 1, 2028 (e)
53.08 %
18.95 %
23.04 %

Revvity Stock Revenue, EBIT, Earnings per Share

The Revvity earnings per share therefore indicates how much revenue Revvity has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
30.21 USD
10.57 USD
7.44 USD
Jan 1, 2022
26.19 USD
6.18 USD
4.50 USD
Jan 1, 2023
22.29 USD
3.24 USD
-0.96 USD
Jan 1, 2024
22.66 USD
3.38 USD
2.43 USD
Jan 1, 2025
25.23 USD
3.15 USD
2.13 USD
Jan 1, 2026 (e)
25.14 USD
4.77 USD
5.36 USD
Jan 1, 2027 (e)
26.49 USD
5.03 USD
5.88 USD
Jan 1, 2028 (e)
28.10 USD
5.33 USD
6.48 USD

Revvity business model & stock analysis

PerkinElmer Inc is an international company headquartered in Waltham, Massachusetts, USA. It provides solutions for improving health and the environment by offering instruments, consumables, software, and services in multiple industries. The company's history began in 1937 when Perkin-Elmer (named after two partners) was founded. It initially focused on manufacturing spectrometers and other instruments for chemical analysis. During World War II, Perkin-Elmer dramatically shifted its business towards the development of rocket sighting devices and aircraft parts. After the war, it returned to producing scientific equipment and began expanding into other markets. In the 1960s, Perkin-Elmer entered the field of medical diagnostics and started developing solutions for measuring hormones and proteins. Over the following decades, the company grew through expansion and acquisitions, including the purchase of Applied Biosystems, in areas such as molecular diagnostics, chromatography, genomics, and environmental analytics. PerkinElmer's business model focuses on providing solutions for customers in various fields such as pharma and biotechnology, environment and food, diagnostics, and clinical research. This includes instruments and consumables for analyzing proteins, nucleic acids, and other chemical substances, molecular diagnostic instruments and software, imaging systems for drug screening, and computer platforms for processing large amounts of data. The offered products and services of PerkinElmer encompass a wide range of solutions. The company's chromatography division offers instruments and consumables for the separation and analysis of chemical compounds. The Environmental Health division provides solutions for the identification and monitoring of pollutants in the environment, as well as for investigating food and drugs. The Analytical Sciences service division offers a wide range of analytical services to assist customers in solving research and development challenges. Other products and services of PerkinElmer include solutions for genomic analysis, drug development and manufacturing, diagnostic systems, laboratory automation, as well as software and services for data management. PerkinElmer is also a major provider of instruments and services in the field of medical imaging. One of PerkinElmer's standout products is its solutions for DNA and RNA sequencing. Using these technologies, researchers can identify genetic information that is crucial for disease diagnosis and treatment, as well as the development of new therapies and drugs. Overall, PerkinElmer offers a broad range of offerings aimed at improving health, the environment, and quality of life. The company works closely with customers in various industries to tailor its offerings to their needs. PerkinElmer is a key provider of solutions for improving health and the environment. The company offers a wide range of products and services, including instruments and consumables for chromatography, solutions for genomic analysis, and imaging systems for drug screening. Through its close collaboration with customers in various industries, PerkinElmer uses its knowledge and technology to make the world a better place.

Revvity SWOT Analysis

Strengths

1. Strong market presence: PerkinElmer Inc has established itself as a leading player in the scientific research and diagnostics sector, with a wide range of products and services.

2. Technological expertise: The company possesses advanced technologies and innovative solutions, giving it a competitive edge in the market.

3. Diversified product portfolio: PerkinElmer offers a diverse range of products across various segments, including life sciences, diagnostics, environmental testing, and food safety.

Weaknesses

1. Dependence on key customers: PerkinElmer relies heavily on a few large customers for a significant portion of its revenue, which exposes it to potential risks if any of these customers reduce their business or switch to competitors.

2. High research and development costs: Developing and maintaining advanced technologies requires substantial investments, which may strain the company's financial resources.

Opportunities

1. Growing demand for diagnostics: The increasing prevalence of diseases and the need for early detection and accurate diagnosis provide a significant growth opportunity for PerkinElmer in the diagnostics market.

2. Expansion in emerging markets: PerkinElmer can explore untapped markets in developing countries, leveraging its expertise to cater to the rising demand for scientific research and diagnostics solutions.

3. Acquisitions and partnerships: Strategic acquisitions or partnerships with complementary companies can help PerkinElmer expand its product offerings and broaden its customer base.

Threats

1. Intense competition: The scientific research and diagnostics market is highly competitive, with numerous established players and new entrants. PerkinElmer must continually innovate to stay ahead.

2. Regulatory challenges: Changes in regulations and compliance requirements can affect the company's operations, potentially leading to increased costs or barriers to market entry.

3. Economic downturns: Global economic uncertainties and recessions can impact the demand for PerkinElmer's products and services, as customers may reduce spending on research and diagnostics.

Revvity Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revvity Employees
Details
Date
Revvity Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Revvity Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Revvity historical P/E ratio, EBIT multiple, and P/S ratio

Revvity annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Revvity shares outstanding

The number of shares of Revvity was 113.21 M in 2025. This indicates how many shares Revvity is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
126.72 M Stocks
Jan 1, 2022
126.48 M Stocks
Jan 1, 2023
123.43 M Stocks
Jan 1, 2024
121.58 M Stocks
Jan 1, 2025
113.21 M Stocks
Jan 1, 2026 (e)
113.21 M Stocks
Jan 1, 2027 (e)
113.21 M Stocks
Jan 1, 2028 (e)
113.21 M Stocks

Revvity Dividend History

37 years of dividend payments

YearAnnual DividendYoY ChangePayments
20260.14USDYTD
Jan 16, 20260.07USD 0.0%1/2
Apr 17, 20260.07USD 0.0%2/2
20250.28USD 0.0%
Jan 17, 20250.07USD 0.0%1/4
Apr 17, 20250.07USD 0.0%2/4
Jul 18, 20250.07USD 0.0%3/4
Oct 17, 20250.07USD 0.0%4/4
20240.28USD 0.0%
20230.28USD 0.0%
20220.28USD 0.0%
20210.28USD 0.0%
20200.28USD 0.0%
20190.28USD 0.0%
20180.28USD 0.0%
20170.28USD 0.0%

Revvity dividend history and estimates

In 2025, Revvity paid a dividend amounting to 0.28 USD. Dividend means that Revvity distributes a portion of its profits to its owners.
  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
0.28 USD
0.00 USD
Jan 1, 2022
0.28 USD
0.00 USD
Jan 1, 2023
0.28 USD
0.00 USD
Jan 1, 2024
0.28 USD
0.00 USD
Jan 1, 2025
0.28 USD
0.00 USD
Jan 1, 2026 (e)
0.07 USD
0.21 USD
Jan 1, 2027 (e)
0.00 USD
0.28 USD
Jan 1, 2028 (e)
0.00 USD
0.28 USD

Revvity dividend payout ratio

In 2025, Revvity had a payout ratio of 13.12%. The payout ratio indicates the percentage of the company's profits that Revvity distributes as dividends.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
3.76 %
Jan 1, 2022
6.22 %
Jan 1, 2023
-29.19 %
Jan 1, 2024
11.51 %
Jan 1, 2025
13.12 %
Jan 1, 2026 (e)
5.23 %
Jan 1, 2027 (e)
4.76 %
Jan 1, 2028 (e)
4.32 %

Current Revvity forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
1.30 %
Buy
57.69 % (15)
Hold
38.46 % (10)
Sell
3.85 % (1)
12M Price Target
118.83
Last Price
124.75
Currency
USD
12M Return Potential
-4.75 %
LTM Return
0 %

Revvity Analyst Rating Actions

DateFirmActionRatingReliability
8/5/2026
Evercore ISI Group
Evercore ISI Group
MaintainedOutperform62
7/6/2026
Evercore ISI Group
Evercore ISI Group
MaintainedOutperform62
5/7/2026
Barclays
Barclays
MaintainedEqual Weight56
5/6/2026
TD Cowen
TD Cowen
MaintainedBuy58
5/6/2026
Stifel
Stifel
MaintainedHold56
5/6/2026
JP Morgan
JP Morgan
MaintainedNeutral61
5/4/2026
Baird
Baird
MaintainedOutperform56
4/14/2026
Goldman Sachs
Goldman Sachs
MaintainedNeutral51
4/14/2026
Barclays
Barclays
DowngradeOverweightEqual Weight56
3/31/2026
JP Morgan
JP Morgan
MaintainedNeutral61

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Revvity Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/4/20261.25USD-723.86 MUSD-2026 Q2
5/5/20261.04USD-717.86 MUSD-2026 Q1
2/2/20261.58USD-776.64 MUSD-2025 Q4
5/9/20241.04USD-660.53 MUSD-2024 Q1
2/12/20241.17USD-683.14 MUSD-2023 Q4

EESG©

Eulerpool ESG Scorecard© for the Revvity stock

88/100
99
Environment
99
Social
67
Governance
E

Environment

20
Scope 1 - Direct Emissions2,121
Scope 2 - Indirect emissions from purchased energy29,581
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions31,702
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees47
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Revvity shareholder structure

% Name
19.57878%
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
8.89942%
PRICE T ROWE ASSOCIATES INC /MD/
PRICE T ROWE ASSOCIATES INC /MD/
7.76227%
EDGEPOINT INVESTMENT GROUP INC.
EDGEPOINT INVESTMENT GROUP INC.
7.36296%
JANUS HENDERSON GROUP PLC
JANUS HENDERSON GROUP PLC
6.46497%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
6.39476%
BLACKROCK, INC.
BLACKROCK, INC.
...

Revvity Beneficial Ownership Filings (SEC 13D/G)

Free Float
91.6%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
19.80%
T. Rowe Price Investment Management, Inc.
T. Rowe Price Investment Management, Inc.
SEC ↗
9.00%
T. Rowe Price Associates, Inc.
T. Rowe Price Associates, Inc.
SEC ↗
7.44%
Vanguard Capital Management
Vanguard Capital Management
SEC ↗
7.39%
EdgePoint Investment Group Inc.
EdgePoint Investment Group Inc.
SEC ↗
6.60%
JANUS HENDERSON GROUP PLC
JANUS HENDERSON GROUP PLC
SEC ↗
5.30%
52-0556948
52-0556948
SEC ↗
5.10%
EIN #00-0000000
EIN #00-0000000
SEC ↗

Revvity Executives and Management Board

15 members · avg. age 58 · 33 % women

PS

Dr. Prahlad Singh (60)

President, Chief Executive Officer, Director · since 2016

11.93 M USD

Management

JG

Mr. Joel Goldberg (56)

Senior Vice President - Administration, General Counsel, Secretary

3.38 M USD
MK

Mr. Maxwell Krakowiak (35)

Chief Financial Officer, Senior Vice President

3.25 M USD
MV

Ms. Miriame Victor (44)

Chief Commercial Officer, Senior Vice President

2.48 M USD
TV

Mr. Tajinder Vohra (59)

Senior Vice President - Global Operations

2.31 M USD
AG

Mrs. Anita Gonzales (49)

Vice President, Controller

Board of Directors

AM

Mr. Alexandros Michas (67)

Independent Non-Executive Chairman of the Board

449,995.00 USD
SV

Dr. Sophie Vandebroek (63)

Independent Director

362,430.00 USD
MK

Mr. Michael Klobuchar (49)

Independent Director

357,430.00 USD
SC

Mr. Samuel Chapin (67)

Independent Director

339,933.00 USD
PB

Dr. Peter Barrett (72)

Independent Director

334,933.00 USD
MV

Mr. Michel Vounatsos (63)

Independent Director

329,933.00 USD

Frequently asked questions about Revvity

PerkinElmer Inc. is a company that focuses on providing products and services in the fields of diagnostics, life sciences, and applied services. Their business model revolves around offering innovative solutions for the healthcare and scientific community. With a wide range of product offerings, including instruments, reagents, consumables, software, and services, PerkinElmer Inc. aims to support scientific research, drug discovery, and diagnostics. By leveraging their expertise in detecting and analyzing biological and environmental challenges, the company strives to enable its customers to improve human and environmental health. PerkinElmer Inc.'s commitment to delivering advanced solutions makes it a trusted partner in the life sciences industry.

PerkinElmer Inc is primarily active in the scientific research and diagnostics industries.

PerkinElmer Inc faces competition from various companies in the market. Some of the main competitors of PerkinElmer Inc include Thermo Fisher Scientific Inc, Agilent Technologies Inc, Waters Corporation, and Bio-Rad Laboratories Inc. These companies also operate in the life science and analytical instrument industries, providing similar products and services. However, PerkinElmer Inc maintains a strong position in the market, leveraging its technological advancements, product innovation, and customer-centric approach to stay competitive in the industry.

PerkinElmer Inc is a highly recognized company in the field of diagnostics, life science research, and applied services. With a rich history dating back to 1937, PerkinElmer Inc has established itself as a global leader in providing innovative solutions to the scientific community. The company's commitment to improving human and environmental health is evident through its extensive range of products, technologies, and services. PerkinElmer Inc actively collaborates with research institutions, pharmaceutical companies, and government agencies to deliver cutting-edge solutions for various scientific challenges. Continuously evolving and expanding, PerkinElmer Inc remains dedicated to driving advancements and enabling breakthrough discoveries in the realms of health, safety, and environmental sustainability.

PerkinElmer Inc has accomplished several significant milestones throughout its history. With over 80 years of experience, the company has become a global leader in providing scientific solutions and technologies. Some notable achievements include the development of innovative diagnostic tools that have revolutionized healthcare, the continuous expansion of its product offering to various industries, and strategic partnerships with leading organizations. PerkinElmer Inc has also received recognition for its commitment to sustainability and social responsibility. These achievements have solidified PerkinElmer Inc's reputation as a trusted provider of high-quality scientific products and services, driving its continuous growth in the market.

PerkinElmer Inc is primarily present in various countries and regions worldwide. As a global leader in life sciences and diagnostics, PerkinElmer has a strong presence in North America, Europe, Asia Pacific, and Latin America. The company operates in over 150 countries, serving customers in academic institutions, government organizations, pharmaceutical companies, and research laboratories. With its expansive reach, PerkinElmer aims to provide innovative solutions and technologies to support advancements in human and environmental health across international borders.

PerkinElmer Inc is a leading global company that specializes in providing innovative solutions for diagnostics, life sciences, and applied services. The company aims to improve the health and well-being of people worldwide through its advanced technologies and scientific expertise. PerkinElmer Inc is committed to delivering reliable and accurate results to its customers, ensuring high-quality products and services. The company's corporate philosophy revolves around promoting sustainability, diversity, and social responsibility. With a strong focus on research and development, PerkinElmer Inc continually strives to drive technological advancements in various industries, making it a trusted leader in its field.

Analysts currently set an average price target of 120.44 USD for the Revvity stock (median: 118.83 USD), implying -3.5 % versus the latest price. The consensus is based on 26 analyst ratings.

26 analysts currently rate the Revvity stock: 15 recommend buying, 10 holding and 1 selling. For 2026, analysts expect Revvity to generate revenue of 2.85 B USD and earnings per share of 5.36 USD.

Converted at the current exchange rate, the Revvity share trades at 106.79 EUR (124.75 USD).

The Revvity share (RVTY) is listed on 7 stock exchanges, including: NYSE (PKI), Frankfurt (PKN.F), München (PKN.MU), Düsseldorf (PKN.DU), London (0KHE.L), London (0KHE.L), SIX (Zürich) (PKN.SW).

PerkinElmer Inc. is an internationally operating company specializing in the provision of products and services in the fields of life sciences, diagnostics, environmental analysis, and other related markets. The company is headquartered in Waltham, Massachusetts and employs over 13,000 employees worldwide. PerkinElmer offers a wide range of products and services tailored to the needs of its customers. In the field of life sciences, PerkinElmer focuses on researching drug candidates to develop new therapeutics and diagnostic methods. The company offers a variety of instruments, software, and reagents that support laboratory analysis. Diagnostics is another important business area for PerkinElmer. In this area, the company provides products that are tailored to the needs of end consumers. This includes devices for prenatal diagnostics, in-house laboratory diagnostics, and tests in the field of genetic diseases. Another core area of PerkinElmer is environmental analysis. PerkinElmer has a long history in the development and manufacture of instruments and consumables used to identify environmental pollutants and other similar influences. The product range includes chromatography equipment, mass spectrometers, reactive chemicals, and software solutions. PerkinElmer is also active in the field of food analysis. This includes products for the identification of food allergens, analysis of nutritional aspects, and residues of pesticides and other pollutants. Another division involves supporting customers with technical support, such as installation and commissioning of instruments, application questions, and the development of test methods. PerkinElmer also offers research and development services tailored to the needs of its customers. These services include the validation of test methods, testing for the detection of pollutants, and the introduction of automation solutions in the production process. PerkinElmer has expanded its business model to fully meet the needs of its customers. The company builds on its strong expertise and history to offer high-quality products and services. Due to its wide range of products and services, PerkinElmer has expanded into several international markets. The company strives to initiate acquisitions and mergers to continuously expand its business areas. The geographical expansion efforts are primarily focused on Asian countries and other emerging markets. Thanks to its broad product range, targeted services, and international presence, PerkinElmer can make a significant contribution to meeting the requirements and needs of its customers.

The expected revenue of Revvity is 2.85 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Revvity is 607.21 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Revvity is currently 23.26. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Revvity stock.

The price-to-sales ratio (P/S) of Revvity is currently 4.95. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Revvity stock.

The Eulerpool Quality Score for Revvity is 1/10.

The ISIN of Revvity is US7140461093. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Revvity is 850943. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Revvity is RVTY. The ticker symbol is used to trade Revvity shares on the stock exchange.

Over the past 12 months, Revvity paid a dividend of 0.28 USD . This corresponds to a dividend yield of about 0.22 %. For the coming 12 months, Revvity is expected to pay a dividend of 0.28 USD.

The current dividend yield of Revvity is 0.22 %.

Revvity pays a dividend, distributed in the months of , , , .

Revvity paid dividends every year for the past 36 years.

For the upcoming 12 months, dividends amounting to 0.28 USD are expected. This corresponds to a dividend yield of 0.22 %.

Revvity is assigned to the 'Health' sector.

To receive the latest dividend of Revvity from amounting to 0.07 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Revvity distributed 0.28 USD as dividends.

The dividends of Revvity are distributed in USD.

All fundamentals and in-depth analysis of Revvity

Our stock analysis for Revvity stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Revvity. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.